+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phe22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme



Phe22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme



Journal of Cardiovascular Pharmacology 26(Suppl. 3): S72



To develop a new family of endothelin-converting enzyme (ECE) inhibitors, we assessed the inhibitory properties of an N- and C-terminal-truncated analogue of big endothelin (ET)-1[1-38], [Phe22]-big-ET-1 [19-37], on the renal vasoconstrictor properties of big ET-1 and ET-1. We had previously shown that a 60-min infusion of phosphoramidon (100 microM) potently inhibits big-ET-1 but not ET-1-induced vasoconstriction in the rabbit perfused kidney. A 1-min preinfusion of the analogue (100 microM) was sufficient to markedly blunt the vasoconstrictor actions of big ET-1 (250 pmol) (control 19.3 +/- 1.0 mm Hg; in presence of [Phe22]-big ET-1[19-37] 4.8 +/- 1.6 mm Hg; n = 6, p < 0.001). A 10- and 60-min preinfusion of the substrate analogue at concentrations of 50 and 5 microM, respectively, reduced the response of big ET-1 to 9.3 +/- 2.3 mm Hg and 3.6 +/- 1.8 mm Hg (n = 3, p < 0.01 compared to control). [Phe22]-big ET-1[19-37] was inactive against ET-1-induced vasoconstriction (10 pmol) and was devoided of intrinsic vasoactivity. All experiments were performed on kidneys pretreated with SQ-28603 (1 microM), a neutral endopeptidase inhibitor. Our results suggest that [Phe22]-big ET-1[19-37] may be a useful lead molecule for the development of more selective and enzyme-resistant inhibitors of the membrane-bound ECE.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046973080

Download citation: RISBibTeXText

PMID: 8587472


Related references

(Phe-22)-big endothelin-1(19-37): A new and potent inhibitor of the endothelin-converting enzyme. Journal of Cardiovascular Pharmacology 26(Suppl. 3): S72-S74, 1995

Big endothelin-1 A new and potent inhibitor of the endothelin-converting enzyme. Journal of Cardiovascular Pharmacology 26(Suppl. 3): S72-S74, 1995

Attenuation of hemolysate-induced cerebrovascular endothelial cell injury and of production of endothelin-1 and big endothelin-1 by an endothelin-converting enzyme inhibitor. Surgical Neurology 58(3-4): 181-188, September-October, 2002

Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circulation Research 78(2): 322-328, 1996

Studies with CGS 26303, an inhibitor of endothelin converting enzyme, supports the presence of intracellular endothelin-converting enzyme in human vascular smooth muscle cells. British Journal of Pharmacology 126(PROC Suppl. ): 50P, 1999

Synthesis of the first highly potent inhibitor of the three vasopeptidases Endothelin converting enzyme , angiotensin converting enzyme and neprilysin. Journal of Peptide Science 8(Suppl.): S100, 2002

Contraction to big endothelin, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi. British Journal of Pharmacology 129(1): 170-176, 2000

Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor. Journal of Cardiovascular Pharmacology 31(Suppl. 1): S68, 1998

Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066. Journal of Cardiovascular Pharmacology 36(5 Suppl 1): S36, 2000

The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1. British Journal of Pharmacology 152(3): 313-322, 2007

The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sciences 91(13-14): 743-748, 2012

SLV306, a novel endothelin converting enzyme and neutral endopeptidase inhibitor prevents systemic conversion of infused big endothelin-1 in humans. British Journal of Pharmacology 137(Proceedings Suppl.): 62P, 2002

Phosphoramidon a metalloproteinase inhibitor suppresses the secretion of endothelin 1 from cultured endothelial cells by inhibiting a bid endothelin 1 converting enzyme. Biochemical and Biophysical Research Communications 171(2): 669-675, 1990

Inhibition of big endothelin-1 responses in endothelium-denuded human coronary artery by the selective endothelin-converting enzyme-1 inhibitor PD159790. British Journal of Pharmacology 126(PROC Suppl. ): 193P, 1999

Comparison of effects a specific endothelin-converting enzyme inhibitor on cardiorenal and neurohumoral functions with endothelin A receptor antagonism in heart failure. Circulation 98(17 Suppl. ): I725, 1998